208 related articles for article (PubMed ID: 30233199)
21. Priapism in sickle-cell disease: a hematologist's perspective.
Kato GJ
J Sex Med; 2012 Jan; 9(1):70-8. PubMed ID: 21554552
[TBL] [Abstract][Full Text] [Related]
22. Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease.
Schnog JB; Teerlink T; van der Dijs FP; Duits AJ; Muskiet FA;
Ann Hematol; 2005 May; 84(5):282-6. PubMed ID: 15599544
[TBL] [Abstract][Full Text] [Related]
23. GlycA is not a useful biomarker of inflammation in sickle cell disease.
Weisman JK; Meeks D; Mendelsohn L; Remaley AT; Sampson M; Allen DT; Nichols J; Shet AS; Thein SL
Int J Lab Hematol; 2018 Dec; 40(6):704-709. PubMed ID: 30152174
[TBL] [Abstract][Full Text] [Related]
24. Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state.
Sins JWR; Schimmel M; Luken BM; Nur E; Zeerleder SS; van Tuijn CFJ; Brandjes DPM; Kopatz WF; Urbanus RT; Meijers JCM; Biemond BJ; Fijnvandraat K
J Thromb Haemost; 2017 Jul; 15(7):1392-1402. PubMed ID: 28457019
[TBL] [Abstract][Full Text] [Related]
25. Effects of hydroxyurea and L-arginine on the production of nitric oxide metabolites in cultures of normal and sickle erythrocytes.
Nahavandi M; Tavakkoli F; Millis RM; Wyche MQ; Habib MJ; Tavakoli N
Hematology; 2006 Aug; 11(4):291-4. PubMed ID: 17178670
[TBL] [Abstract][Full Text] [Related]
26. Ocular manifestations of sickle cell disease at the Korle-bu Hospital, Accra, Ghana.
Osafo-Kwaako A; Kimani K; Ilako D; Akafo S; Ekem I; Rodrigues O; Enweronu-Laryea C; Nentwich MM
Eur J Ophthalmol; 2011; 21(4):484-9. PubMed ID: 21058274
[TBL] [Abstract][Full Text] [Related]
27. Plasma levels of TNF-alpha in sickle cell patients receiving hydroxyurea.
Tavakkoli F; Nahavandi M; Wyche MQ; Perlin E
Hematology; 2004 Feb; 9(1):61-4. PubMed ID: 14965870
[TBL] [Abstract][Full Text] [Related]
28. Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease.
Morris CR; Kuypers FA; Larkin S; Sweeters N; Simon J; Vichinsky EP; Styles LA
Br J Haematol; 2000 Nov; 111(2):498-500. PubMed ID: 11122090
[TBL] [Abstract][Full Text] [Related]
29. Priapism in sickle cell disease: Associations between NOS3 and EDN1 genetic polymorphisms and laboratory biomarkers.
Figueiredo CVB; Santiago RP; da Guarda CC; Oliveira RM; Fiuza LM; Yahouédéhou SCMA; Carvalho SP; Neres JSDS; Oliveira AMJ; Fonseca CA; Nascimento VML; Lyra IM; Aleluia MM; Goncalves MS
PLoS One; 2021; 16(2):e0246067. PubMed ID: 33539452
[TBL] [Abstract][Full Text] [Related]
30. Relevance of fibrinolytic protein (D-dimer) and fibrinopeptide A as markers of sickle cell anaemia vaso-occlusive crisis.
Ekwere TA; Ebele U; Ekanem M; Ogunro PS
Niger Postgrad Med J; 2014 Sep; 21(3):225-30. PubMed ID: 25331238
[TBL] [Abstract][Full Text] [Related]
31. Pregnancy outcomes among patients with sickle cell disease at Korle-Bu Teaching Hospital, Accra, Ghana: retrospective cohort study.
Wilson NO; Ceesay FK; Hibbert JM; Driss A; Obed SA; Adjei AA; Gyasi RK; Anderson WA; Stiles JK
Am J Trop Med Hyg; 2012 Jun; 86(6):936-42. PubMed ID: 22665597
[TBL] [Abstract][Full Text] [Related]
32. Oxidative Profile of Patients with Sickle Cell Disease.
Antwi-Boasiako C; Dankwah GB; Aryee R; Hayfron-Benjamin C; Donkor ES; Campbell AD
Med Sci (Basel); 2019 Jan; 7(2):. PubMed ID: 30691006
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of psychological symptoms among adults with sickle cell disease in Korle-Bu Teaching Hospital, Ghana.
Anim MT; Osafo J; Yirdong F
BMC Psychol; 2016 Nov; 4(1):53. PubMed ID: 27832817
[TBL] [Abstract][Full Text] [Related]
34. Monocytosis is associated with hemolysis in sickle cell disease.
Wongtong N; Jones S; Deng Y; Cai J; Ataga KI
Hematology; 2015 Dec; 20(10):593-7. PubMed ID: 25875078
[TBL] [Abstract][Full Text] [Related]
35. Abnormality of erythrocyte membrane n-3 long chain polyunsaturated fatty acids in sickle cell haemoglobin C (HbSC) disease is not as remarkable as in sickle cell anaemia (HbSS).
Ren H; Ghebremeskel K; Okpala I; Ugochukwu CC; Crawford M; Ibegbulam O
Prostaglandins Leukot Essent Fatty Acids; 2006 Jan; 74(1):1-6. PubMed ID: 16314081
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of treatment patterns, healthcare resource utilization and cost of illness for sickle cell disease in Ghana: a private medical insurance claims database study.
Marfo K; Dei-Adomakoh Y; Segbefia C; Dwomoh D; Edgal A; Ampah N; Ramachandrachar BC; Subramanyam K; Natarajan A; Egbujo O; Ataga KI
BMC Health Serv Res; 2023 Sep; 23(1):1018. PubMed ID: 37735428
[TBL] [Abstract][Full Text] [Related]
37. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.
Kato GJ; McGowan V; Machado RF; Little JA; Taylor J; Morris CR; Nichols JS; Wang X; Poljakovic M; Morris SM; Gladwin MT
Blood; 2006 Mar; 107(6):2279-85. PubMed ID: 16291595
[TBL] [Abstract][Full Text] [Related]
38. Plasma levels of some coagulation parameters in steady state HBSC disease patients.
Ajuwon MD; Olayemi E; Benneh AA
Pan Afr Med J; 2014; 19():289. PubMed ID: 25870744
[TBL] [Abstract][Full Text] [Related]
39. Cytokine profile of sickle cell disease in Oman.
Pathare A; Al Kindi S; Alnaqdy AA; Daar S; Knox-Macaulay H; Dennison D
Am J Hematol; 2004 Dec; 77(4):323-8. PubMed ID: 15551290
[TBL] [Abstract][Full Text] [Related]
40. Lactate dehydrogenase and hemolysis index to predict vaso-occlusive crisis in sickle cell disease.
Feugray G; Dumesnil C; Grall M; Benhamou Y; Girot H; Fettig J; Brunel V; Billoir P
Sci Rep; 2023 Dec; 13(1):21198. PubMed ID: 38040880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
